The Study of Genetic Mutations in Gene IKBKG in Bloch-Siemens Syndrome
Shahin Asadi*, Mahsa Jamali, Soheil Nemati Arzeloo and Mona Habashizadeh
Division of Medical Genetics and Molecular Pathology Research, Tabriz university of Medical Sciences, Iran
Submission: May 09, 2019; Published: July 26, 2019
*Corresponding author: Shahin Asadi, Tabriz university of Medical Sciences, Director of the Division of Medical Genetics and Molecular Research, Tabriz, Iran
How to cite this article: Shahin Asadi*, Mahsa Jamali, Soheil Nemati Arzeloo and Mona Habashizadeh. The Study of Genetic Mutations in Gene IKBKG in Bloch-Siemens Syndrome. Curr Trends Biomedical Eng & Biosci. 2024; 19(3): 556014. DOI:10.19080/CTBEB.2024.19.556014
Abstract
The Bloch-Siemens syndrome is a genetic dermatological disorder affecting the skin, hair, teeth, and central nervous system. Progressive skin changes occur in four stages, the first of which appear in early infancy or can be present at birth. This syndrome is an X-linked dominant genetic disorder caused by mutations in the IKBKG gene.
Keywords: Bloch Siemens syndrome; Genetic dermatological disorder; Mutations in the IKBKG gene
Introduction
Generalizations of the Bloch-siemens syndrome
The Bloch-Siemens syndrome is a genetic disorder that can affect many body systems, especially the skin. The syndrome is more common in women than in men [1].
Clinical signs and symptoms of Bloch-siemens syndrome
Skin disorders appear in children with a childhood, adolescence, or youth. Many newborns with this syndrome reveal mild rashes at birth, which are later recovered and subsequently grow into warts in the skin. In the early days of childhood, the skin produces gray and brown plates that occur in a rotating pattern. These plaques disappear over time, and adults with this syndrome reveal unusual skin lines (hypopigmentation) on the arms and legs [1] (Figure 1).

The other Symptoms and Signs Bloch-Siemens syndrome can include hair loss (alopecia) that affects the scalp and other parts of the body, dental disorders (such as minor teeth or dental congestion) and eye disorders that can lead to Lose sight. Most people with Bloch-Siemens syndrome have normal intelligence. However, Bloch-Siemens syndrome may also affect the brain. Brain-related problems in the Bloch-Siemens syndrome can include delay in the development of mental skills, intellectual disability, seizure and other neurological problems [2-5] (Figure 2).

Etiology of the Bloch-siemens syndrome
The Bloch-Siemens syndrome is caused by the mutation of the IKBKG gene that is based on the Xq28 long arm of the X chromosome X. The gene provides instructions for protein synthesis that helps to regulate the kappa factor B nuclear factor. The Kappa B nuclear factor is a group of regulatory proteins that help protect certain cells from suicide (apoptosis) in response to certain signals [6-7] (Figure 3).

Approximately 80% of people with Bloch-Siemens syndrome have a knockout mutation in the IKBKG gene that removes some genetic material from the gene. This knockout mutation probably leads to the production of IKBKG abnormal and short-acting pterothene. Other people with Bloch-Siemens syndrome have mutations that prevent the production of IKBKG proteins. Without this protein, the Kappa B nuclear factor is not properly regulated and the cells become sensitive to signals that lead them to suicide. Researchers believe that this abnormal cell death leads to signs and symptoms of the Bloch-Siemens syndrome [9] (Figure 4).


The Bloch-Siemens syndrome follows the predominant X-dominant hereditary pattern. Therefore, to produce this syndrome, a mutation version of the IKBKG gene (parent or parent) is required, and the chance of having a child with a Bloch-Siemens syndrome is 50% for each pregnancy [9] (Figure 5).
Frequency of Bloch-siemens syndrome
The Bloch-Siemens syndrome is an unusual skin disorder that has been reported in medical literature for about 900 to 1200 people worldwide worldwide. It is worth noting that most people with Bloch-Siemens syndrome are women [10].
Diagnosis of Bloch-siemens syndrome
The Bloch-Siemens syndrome is diagnosed based on the clinical and physical findings of the patients and some pathological tests. The most definite diagnostic method for this syndrome is the molecular genetic testing of the IKBKG gene to investigate the presence of possible mutations. Prenatal diagnosis is also possible by using the PGD technique and amniocentesis fluid or by sampling the embryo’s chorionic pelvis. The diagnosis of Bloch-Siemens syndrome is based on clinical evaluation, detailed patient history, and molecular genetic testing for mutation in the IKBKG gene. IKBKG is the only gene known to be associated with Bloch-Siemens syndrome. 65 percent of patients have a specific deletion within the gene. Another 20 percent or so have mutations found by gene sequencing. A skin biopsy to confirm the diagnosis in a female is now rarely needed given the widespread availability and sensitivity of molecular genetic testing. Nonetheless, skin biopsy may be helpful in confirming the diagnosis in a female with borderline or questionable findings in whom molecular genetic testing has not identified a disease-causing mutation [11] (Figure 6).

Treatment routes for the Bloch-siemens syndrome
The treatment and management strategy of Bloch-Siemens syndrome is symptomatic and supportive. Treatment may be done by a team of professionals, including pediatricians, dermatologists, dental practitioners, eye specialists and other healthcare professionals. Skin abnormalities characteristic of Bloch-Siemens syndrome usually disappear by adolescence or adulthood without any treatment.
Cryotherapy and laser photocoagulation may be used to treat affected individuals with retinal neovascularization that predisposes to retinal detachment. Dental abnormalities can often be treated effectively by dentists who may provide dental implants in childhood as needed. Also if dental abnormalities interfere with chewing and/or speech, assistance from a speech pathologist and/or pediatric nutritionist may be necessary. Hair problems may require the attention of a dermatologist in some cases, although they are usually not severe. Neurological symptoms such as seizures, muscle spasms or mild paralysis may be controlled with various drugs and/or medical devices [12]. There is no definite treatment for this syndrome and all clinical measures are needed to reduce the suffering of the infected person. Genetic counseling is also a special place for all parents who want a healthy baby [12].
Discussion and Conclusion
The Bloch-Siemens syndrome was named based on the appearance of the skin under the microscope during the later stages of the condition. The Bloch-Siemens syndrome is a genetic dermatological disorder affecting the skin, hair, teeth, and central nervous system. Progressive skin changes occur in four stages, the first of which appear in early infancy or can be present at birth. This syndrome is an X-linked dominant genetic disorder caused by mutations in the IKBKG gene. There is no definite treatment for this syndrome and all clinical measures are needed to reduce the suffering of the infected person. Genetic counseling is also a special place for all parents who want a healthy baby.
History of the Bloch-siemens syndrome
The Bloch-Siemens syndrome was first reported in 1926 by Dr. Bruno Bloch, a dermatologist from Switzerland, and in 1928 by Dr. Marion Sulzberger, a dermatologist from the United States [12] (Figure 7).

References
- Ardelean D, Pope E (2006) Incontinentia pigmenti in boys: a series and review of the literature. Pediatr Dermatol 23(6): 523-527.
- Berlin AL, Paller AS, Chan LS (2002) Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. J Am Acad Dermatol 47(2):169-187.
- Bruckner AL (2004) Incontinentia pigmenti: a window to the role of NF-kappaB function. Semin Cutan Med Surg 23(2):116-124.
- Goldberg MF (2004) The skin is not the predominant problem in incontinentia pigmenti. Arch Dermatol 140(6): 748-750.
- Hadj-Rabia S, Froidevaux D, Bodak N, Hamel-Teillac D, Smahi A, et al. (2003) Clinical study of 40 cases of incontinentia pigmenti. Arch Dermatol 139(9): 1163-1170.
- Happle R (2003) A fresh look at incontinentia pigmenti. Arch Dermatol 139(9):1206-1208.
- Nelson DL (2006) NEMO NFkappaB signaling and incontinentia pigmenti. Curr Opin Genet Dev 16(3): 282-288.
- Scheuerle AE, Ursini MV (1999) Incontinentia Pigmenti. In: Pagon RA, Adam MP, et al. (Eds), GeneReviews®. Seattle (WA): University of Washington, Seattle, USA.
- Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, et al. (2000) Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 405(6785): 466-472.
- Bloch B (1926) Eigentümliche, bisher nicht beschriebene Pigmentaffektion (incontinentia pigmenti). Schweizerische medizinische Wochenschrift. Basel 56: 404-405.
- Sulzberger MB (1927) Über eine bisher nicht beschriebene kongenitale Pigmentanomalie (incontinentia pigmenti). Archiv für Dermatologie und Syphilis. Berlin 154: 19-32.
- Sulzberger MB (1927) Über eine bisher nicht beschriebene kongenitale Pigmentanomalie (incontinentia pigmenti). Berlin: Archiv für Dermatologie und Syphilis. Pp. 154.